362612-66-6

Basic information

• Product Name: 4-(2-THIENYL)PHENYLBORONIC ACID
• Synonyms: 4-(2-THIENYL)PHENYLBORONIC ACID;AKOS BRN-1145;THIOPHEN-2-YL-4-BENZENEBORONIC ACID;4-(2-Thienyl)phenylboronic acid , May contain varying amounts of anhydride, 97%;2-(4-Boronophenyl)thiophene;4-(thiophen-2-yl)phenylboronic acid, 95%
• CAS NO: 362612-66-6
• Molecular Formula: C₁₀H₉BO₂S
• Molecular Weight: 204.05
• Product Categories: Boronic Acids & Esters;Phenyls & Phenyl-Het;Boronic Acids & Esters;Phenyls & Phenyl-Het
• Mol File: 362612-66-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: 249 °C
• Boiling Point: 385.985 °C at 760 mmHg
• Flash Point: 187.237 °C
• Appearance: /
• Density: 1.298 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: 2-8°C
• PKA: 8.39±0.10(Predicted)
• CAS DataBase Reference: 4-(2-THIENYL)PHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-THIENYL)PHENYLBORONIC ACID(362612-66-6)
• EPA Substance Registry System: 4-(2-THIENYL)PHENYLBORONIC ACID(362612-66-6)

Safety Data

• Hazardous Substances Data: 362612-66-6(Hazardous Substances Data)

Usage

Uses

4-(2-Thienyl)phenylboronic acid is used in the preparation of thienyl-capped oligophenylenes.

InChI:InChI=1/C10H9BO2S/c12-11(13)9-5-3-8(4-6-9)10-2-1-7-14-10/h1-7,12-13H

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 851231-30-6 1,3-dimethoxy-2-(4',4',5',5'-tetramethyl-1',3',2'-dioxaborolanyl)-benzene 

Downstream Products

• 42545-43-7 2-(4-methoxyphenyl)thiophene 
• 1618645-45-6 2-{[cyclohexyl(methyl)amino]methyl}-4,6-bis(thiophen-2-yl)aniline 
• 1372413-38-1 methyl 4-amino-3-chloro-6-(4'-(thiophen-2-yl)phenyl)pyridine-2-carboxylate 

Relevant articles and documents

ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS

This invention relates to a class of novel aliphatic amino bis-aryl compounds containing at least four carbon atoms and an amino group either substituted thereon or incorporated therein and is further linked or bridged to two mono- and/or bicyclic rings. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.